Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

McMaster University

$225,676.00

Defining clinically important bleeding outcomes for clinical trials in hematological malignancies: perceptions of patients and health care providers

FY 2020-21

Summary
Patients with acute leukemia bleed more easily due to the disease and its treatments. Researchers use bleeding as an outcome in clinical trials to test new products and better ways to prevent bleeding in these patients. Currently there are four categories of bleeding: levels 1 and 2 represent more mild types of bleeding and levels 3 and 4 are more severe types of bleeding (transfusion needed, vision loss or bleeding into the brain which could cause death). Outcomes used in clinical studies usually combine levels 2, 3 and 4 bleeding, but this is problematic because: the majority of bleeds are mild grade 2 bleeding events, which may not be related to more severe bleeding and may not be important to doctors or concerning to patients. We will explore 3 objectives to define bleeding in patients with acute leukemia that is important to patients and physicians: 1) Information from 3 international studies of 2300 patients will be used to determine whether our recent finding that the symptom of blood in urine predicts more severe bleeding is correct; 2) We will conduct interviews with patients who have received treatment for acute leukemia and physicians and nurses who care for patients with acute leukemia to understand what kind of bleeding is important to them 3) Using interview results and previous work that identified medically important bleeding, a smaller group of interview participants will rate and score the most important bleed items. This information will be used to develop a utility bleeding score (UBS) for use as an outcome in clinical studies. We will send a survey to physicians in different countries who treat leukemia to obtain their input about the UBS and to see if they would accept the use of this new bleeding outcome in future research studies. The findings from this project will help medical researchers to use an outcome that will be important and meaningful for patients and health care providers when performing studies in the acute leukemia population.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
435813
Name
Hillis Christopher M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Health Services Evaluation & Interventions Research 2
Projecttitle
Defining clinically important bleeding outcomes for clinical trials in hematological malignancies: perceptions of patients and health care providers
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$225,676
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Acute Leukemia; Chemotherapy; Hematological Malignancies; Psychosocial Impact Of Bleeding; Risk Of Bleeding; Transfusion Practices; Transplantation; Who Bleeding Grades
Abstract
Patients with acute leukemia bleed more easily due to the disease and its treatments. Researchers use bleeding as an outcome in clinical trials to test new products and better ways to prevent bleeding in these patients. Currently there are four categories of bleeding: levels 1 and 2 represent more mild types of bleeding and levels 3 and 4 are more severe types of bleeding (transfusion needed, vision loss or bleeding into the brain which could cause death). Outcomes used in clinical studies usually combine levels 2, 3 and 4 bleeding, but this is problematic because: the majority of bleeds are mild grade 2 bleeding events, which may not be related to more severe bleeding and may not be important to doctors or concerning to patients. We will explore 3 objectives to define bleeding in patients with acute leukemia that is important to patients and physicians: 1) Information from 3 international studies of 2300 patients will be used to determine whether our recent finding that the symptom of blood in urine predicts more severe bleeding is correct; 2) We will conduct interviews with patients who have received treatment for acute leukemia and physicians and nurses who care for patients with acute leukemia to understand what kind of bleeding is important to them 3) Using interview results and previous work that identified medically important bleeding, a smaller group of interview participants will rate and score the most important bleed items. This information will be used to develop a utility bleeding score (UBS) for use as an outcome in clinical studies. We will send a survey to physicians in different countries who treat leukemia to obtain their input about the UBS and to see if they would accept the use of this new bleeding outcome in future research studies. The findings from this project will help medical researchers to use an outcome that will be important and meaningful for patients and health care providers when performing studies in the acute leukemia population.
Competitiondate
202010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hillis, Christopher M; Heddle, Nancy M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $225,676~ $0~